Albuterol Pediatric Dose — Hyperkalemia (Toxicology)
Albuterol is a selective beta-2 adrenergic agonist that stimulates Na⁺/K⁺-ATPase, promoting intracellular potassium shift and thereby transiently lowering serum potassium levels. In the toxicology and critical care setting, nebulized albuterol is used as an adjunctive agent in the acute management of hyperkalemia. It is particularly useful when combined with other stabilizing and elimination strategies.
Pediatric Dosing
- Hyperkalemia: 5 mg nebulized (fixed dose, not weight-based)
The dose of 5 mg nebulized is a fixed flat dose used for hyperkalemia in pediatric patients, higher than standard bronchodilator dosing, reflecting the supraphysiologic exposure needed to achieve meaningful potassium shift. This dose applies regardless of weight; consult institutional protocol for weight-based thresholds or age-specific adjustments.
Worked example: For a 20 kg child with hyperkalemia, administer 5 mg albuterol via nebulization — the same fixed dose as for other pediatric patients in this indication.
Indications and Clinical Context
Nebulized albuterol is indicated as an adjunctive measure in the acute management of pediatric hyperkalemia, particularly in contexts such as acute kidney injury, rhabdomyolysis, massive transfusion, or medication toxicity (e.g., digoxin, beta-blocker overdose with membrane effects). Beta-2 agonist–mediated potassium shift begins within 30 minutes of administration and can reduce serum potassium by approximately 0.5–1.0 mEq/L, though response is variable.
Albuterol does not eliminate potassium from the body and must be used alongside definitive therapies such as calcium for membrane stabilization, sodium bicarbonate, insulin/dextrose, and renal replacement or elimination strategies as appropriate. This approach aligns with standard PICU and toxicology practice for multi-modal hyperkalemia management.
Administration and Monitoring
Administer 5 mg albuterol via continuous or intermittent nebulization using standard nebulizer equipment. The high dose used for hyperkalemia is well above typical bronchodilator doses and is expected to cause tachycardia; this is an anticipated pharmacologic effect rather than a contraindication in most cases. Monitor heart rate, blood pressure, and serum glucose (beta-2 stimulation can cause hyperglycemia) continuously during administration.
- Route: Nebulized inhalation only per this dosing source
- Onset of potassium-lowering effect: approximately 30 minutes
- Anticipated adverse effects: tachycardia, tremor, hyperglycemia, hypokalemia with repeated dosing
- Use with caution in patients with underlying tachyarrhythmias or those in whom tachycardia is poorly tolerated
- Consult institutional protocol for dosing in neonates or infants and for repeat dosing intervals
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.